Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

被引:56
作者
Bliwise, DL [1 ]
Freeman, A [1 ]
Ingram, CD [1 ]
Rye, DB [1 ]
Chakravorty, S [1 ]
Watts, RL [1 ]
机构
[1] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
关键词
restless legs syndrome; movement disorders; dopamine; ropinirole; sleep; periodic leg movements; pharmacology; clinical trial;
D O I
10.1016/j.sleep.2004.12.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: Restless legs syndrome (RLS) is a condition characterized by an urge to move the legs, usually accompanied by lower limb paresthesias. These symptoms worsen at rest, are relieved by activity, and are worse at night. Previous studies have suggested that dopaminergic drugs such as L-dopa and dopamine agonists, as well as benzodiazepines and opioids, can treat RLS successfully. The purpose of this study was to test the clinical efficacy of ropinirole, a D2/D3 agonist, in the treatment of RLS in a double-blind, short-term, placebo-controlled clinical trial. Patients and methods: After undergoing successful open-label titration and dose adjustments with ropinirole for RLS symptoms over a period of 4 weeks, 22 RLS patients (mean age = 50.8; mean duration of symptoms = 26.1 years) were randomized to receive either placebo (n = 13) or ropinirole (n = 9) for 2 additional weeks. Outcome measures included assessment of periodic leg movements in sleep (PLMS) recorded with nocturnal polysomnography and RLS symptoms as assessed with the International Restless Legs Syndrome Study Group (IRLSSG) Rating Scale. Secondary outcomes included sleep macroarchitecture. Results: Results indicated that relative to placebo, ropinirole, at a mean dose of 1.4 mg HS significantly decreased PLMS and RLS symptoms. Sleep macroarchitecture did not change. Side effects were typical of all dopamine agonists and were dose related. The majority of patients elected to continue treatment with ropinirole upon study completion. Conclusions: Ropinirole successfully treated long-standing RLS and can be considered a viable short-term treatment for this condition. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 39 条
  • [31] Trenkwalder C, 2004, J NEUROL NEUROSUR PS, V75, P92
  • [32] L-DOPA THERAPY OF UREMIC AND IDIOPATHIC RESTLESS LEGS SYNDROME - A DOUBLE-BLIND, CROSSOVER TRIAL
    TRENKWALDER, C
    STIASNY, K
    POLLMACHER, T
    WETTER, T
    SCHWARZ, J
    KOHNEN, R
    KAZENWADEL, J
    KRUGER, HP
    RAMM, S
    KUNZEL, M
    OERTEL, WH
    [J]. SLEEP, 1995, 18 (08): : 681 - 688
  • [33] Striatal dopaminergic function in restless legs syndrome -: 18F-dopa and 11C-raclopride PET studies
    Turjanski, N
    Lee, AJ
    Brooks, DJ
    [J]. NEUROLOGY, 1999, 52 (05) : 932 - 937
  • [34] Prevalence of restless legs syndrome among men aged 18 to 64 years:: An association with somatic disease and neuropsychiatric symptoms
    Ulfberg, J
    Nyström, B
    Carter, N
    Edling, C
    [J]. MOVEMENT DISORDERS, 2001, 16 (06) : 1159 - 1163
  • [35] Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome
    Walters, AS
    LeBrocq, C
    Dhar, A
    Hening, W
    Rosen, R
    Allen, RP
    Trenkwalder, C
    Adler, C
    Newman, S
    Reiners, C
    Aksu, M
    Allen, RP
    Buchholz, D
    Hening, WA
    Anderson, M
    Mosko, S
    Ancoli-Israel, S
    Jimenez, WB
    Hallett, M
    Bassetti, C
    Clavadetscher, S
    Bliwise, DL
    Gurecki, P
    Rye, DB
    Broch, LL
    Zak, R
    Chokroverty, S
    Coccagna, G
    Lugaresi, E
    Miele, F
    Montagna, P
    Plazzi, G
    Provini, F
    de Mello, MT
    Tufik, S
    de Weerd, AW
    Rijsman, RM
    Dhar, A
    LeBrocq, C
    Walters, AS
    Ehrenberg, B
    Eisensehr, I
    Ekbom, K
    Ljungdahl, A
    Garcia-Borreguero, D
    Larrosa, O
    Hening, WA
    Rosen, R
    Walters, AS
    Hening, WA
    [J]. SLEEP MEDICINE, 2003, 4 (02) : 121 - 132
  • [36] A DOUBLE-BLIND RANDOMIZED CROSSOVER TRIAL OF BROMOCRIPTINE AND PLACEBO IN RESTLESS LEGS SYNDROME
    WALTERS, AS
    HENING, WA
    KAVEY, N
    CHOKROVERTY, S
    GIDROFRANK, S
    [J]. ANNALS OF NEUROLOGY, 1988, 24 (03) : 455 - 458
  • [37] TOWARD A BETTER DEFINITION OF THE RESTLESS LEGS SYNDROME
    WALTERS, AS
    [J]. MOVEMENT DISORDERS, 1995, 10 (05) : 634 - 642
  • [38] A randomized controlled study of pergolide in patients with restless legs syndrome
    Wetter, TC
    Stiasny, K
    Winkelmann, J
    Buhlinger, A
    Brandenburg, U
    Penzel, T
    Medori, R
    Rubin, M
    Oertel, WH
    Trenkwalder, C
    [J]. NEUROLOGY, 1999, 52 (05) : 944 - 950
  • [39] Treatment of restless leg syndrome with pergolide - An open clinical trial
    Winkelmann, J
    Wetter, TC
    Stiasny, K
    Oertel, WH
    Trenkwalder, C
    [J]. MOVEMENT DISORDERS, 1998, 13 (03) : 566 - 569